Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...

The FDA has rejected Applied Therapeutics’ attempt to win approval on the strength of a failed phase 3 trial, triggering a 75% drop in the biotech’s share price. Applied said the complete response ...

Alector’s AbbVie-partnered Alzheimer's disease asset has failed to slow disease progression in a phase 2 study, the latest in ...

Roche has struck a $1.5 billion deal to buy Poseida Therapeutics. The takeover will establish off-the-shelf cell therapies, ...

MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...

Roche’s Skyscraper-01 has fallen down. The phase 3 trial found adding the TIGIT candidate tiragolumab to a checkpoint ...

Proliferative vitreoretinopathy (PVR) is an eye condition that leads to blindness and can currently only be addressed with ...

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...

A federal court jury has sided with Guardant Health, which had claimed that rival cancer test developer Natera went too far ...

Outlook Therapeutics’ eye disease drug has failed to match Roche’s Lucentis in a key trial. The biotech brushed off the ...

Medigene will slim its head count by 40% and pause plans to get its first asset into the clinic in order to channel cash to ...

But utreloxastat had little effect on ALS in the phase 2 trial. PTC powered the study to show whether twice-daily oral dosing ...